CLINICAL TRIAL SUMMARY

MDACC Study No:DM02-592 (clinicaltrials.gov NCT No: NCT00503035)
Title:Molecular targeting of 15-LOX-1 for apoptosis induction in human colorectal tumors
Principal Investigator:Imad Shureiqi
Treatment Agent:Celecoxib
Study Status:Closed
Study Description:The goal of this clinical research study is to learn how (Celebrex) celecoxib
affects polyp cells of the colon and rectum.

Hide details for General InformationGeneral Information

Disease Group:Colorectal
Phase of Study:Phase II
Treatment Agents:Celecoxib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:none
Supported By:N/A
Return Visit:one return visit at 6 months of Celecoxib treatment
Home Care:none


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Imad Shureiqi
Dept:Clinical Cancer Prevention
For Clinical Trial Enrollment:713-745-4929
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults